FIBROGEN INC (FGEN) Stock Overview
NASDAQ:FGEN - US31572Q8087 - Common Stock
FGEN Key Statistics, Chart & Performance
The current stock price of FGEN is 12.18 USD. In the past month the price increased by 75.76%. In the past year, price increased by 24.92%.
FGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.01 | 374.37B | ||
| AMGN | AMGEN INC | 13.16 | 154.47B | ||
| GILD | GILEAD SCIENCES INC | 14.56 | 139.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.67 | 102.81B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.59B | ||
| ARGX | ARGENX SE - ADR | 76.2 | 43.23B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.69 | 39.47B | ||
| INSM | INSMED INC | N/A | 30.71B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.19B | ||
| NTRA | NATERA INC | N/A | 23.24B | ||
| BIIB | BIOGEN INC | 8.72 | 20.47B |
Related stock screener links
About FGEN
Company Profile
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. The company is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
Company Info
FIBROGEN INC
350 Bay Street, Suite 100 #6009
San Francisco CALIFORNIA 94158 US
CEO: Enrique Conterno
Employees: 225
Phone: 14159781200
FIBROGEN INC / FGEN FAQ
What is the stock price of FIBROGEN INC today?
The current stock price of FGEN is 12.18 USD. The price increased by 2.96% in the last trading session.
What is the ticker symbol for FIBROGEN INC stock?
The exchange symbol of FIBROGEN INC is FGEN and it is listed on the Nasdaq exchange.
On which exchange is FGEN stock listed?
FGEN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FIBROGEN INC stock?
8 analysts have analysed FGEN and the average price target is 43.86 USD. This implies a price increase of 260.1% is expected in the next year compared to the current price of 12.18. Check the FIBROGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FIBROGEN INC worth?
FIBROGEN INC (FGEN) has a market capitalization of 49.21M USD. This makes FGEN a Nano Cap stock.
How many employees does FIBROGEN INC have?
FIBROGEN INC (FGEN) currently has 225 employees.
What are the support and resistance levels for FIBROGEN INC (FGEN) stock?
FIBROGEN INC (FGEN) has a support level at 11.16. Check the full technical report for a detailed analysis of FGEN support and resistance levels.
Is FIBROGEN INC (FGEN) expected to grow?
The Revenue of FIBROGEN INC (FGEN) is expected to decline by -92.86% in the next year. Check the estimates tab for more information on the FGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy FIBROGEN INC (FGEN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FGEN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FGEN, evaluating the profitability, health, valuation and growth aspects
- FIBROGEN INC (FGEN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FIBROGEN INC (FGEN) Sales and EPS estimates to see what analysts future expectations are.
- FIBROGEN INC (FGEN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FIBROGEN INC (FGEN) Insider and Institutional Ownership to learn about the owners and their transactions.
- FIBROGEN INC (FGEN) Stock Chart to make your own analysis
- FIBROGEN INC (FGEN) Latest news and press-releases to stay up to date.
Does FIBROGEN INC (FGEN) stock pay dividends?
FGEN does not pay a dividend.
When does FIBROGEN INC (FGEN) report earnings?
FIBROGEN INC (FGEN) will report earnings on 2025-11-10, after the market close.
What is the Price/Earnings (PE) ratio of FIBROGEN INC (FGEN)?
FIBROGEN INC (FGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.38).
What is the Short Interest ratio of FIBROGEN INC (FGEN) stock?
The outstanding short interest for FIBROGEN INC (FGEN) is 3.65% of its float. Check the ownership tab for more information on the FGEN short interest.
FGEN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to FGEN. When comparing the yearly performance of all stocks, FGEN is one of the better performing stocks in the market, outperforming 89.23% of all stocks.
FGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FGEN. FGEN may be in some trouble as it scores bad on both profitability and health.
FGEN Financial Highlights
Over the last trailing twelve months FGEN reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS increased by 99.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.16% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FGEN Forecast & Estimates
8 analysts have analysed FGEN and the average price target is 43.86 USD. This implies a price increase of 260.1% is expected in the next year compared to the current price of 12.18.
For the next year, analysts expect an EPS growth of 122.87% and a revenue growth -92.86% for FGEN